Current Pipeline
DISEASE AREA
COMPOUND
INDICATION
DISCOVERY
IND ENABLING
PHASE I
PHASE II
PHASE III
Schizophrenia
NS-136
(mAChR4 PAM)
Schizophrenia Psychosis in Alzheimer's disease
Depression
NS-041
(KCNQ2/3 Opener)
Epilepsy
Mood disorders
Pain
NS-015
(Undisclosed)
Treatment-resistant depression
NS-031
(Undisclosed)
Treatment-resistant depression
Neurological Disorders
NS-050
(Undisclosed)
Alzheimer's disease Parkinson’s disease
N-999
(Undisclosed)
Alzheimer's disease Parkinson’s disease
Clinical Trials
COMPOUND
INDICATION
STAGE
STUDY DESCRIPTION
STATUS
NS-136
Schizophrenia
Psychosis in
Alzheimer's disease
Phase I
A Phase 1, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and PK of Single and Multiple Ascending Oral Doses and Food Effect of NS-136 in Healthy Subjects
View StudyRecruiting
NS-041
Epilepsy
Mood disorders
Pain
Phase I
A Phase 1, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and PK of Single and Multiple Ascending Oral Doses and Food Effect of NS-041 in Healthy Subjects
View StudyRecruiting
Publications
